Homology Medicines
Homology Medicines raises $127M Series C at $1B valuation
Homology Medicines: Series C Funding Round
Homology Medicines has successfully raised $127M in Series C funding, reaching a valuation of $1B.
Company Overview
Genetic medicines platform
Funding Details
The Series C round was led by ARCH Venture Partners, with participation from Temasek Holdings, Fidelity, Deerfield Management.
Company Information
- Headquarters: 45 Wiggins Avenue, Bedford, MA 01730
- Founded: 2015
- Employees: 200+
- Category: Biotech
Investment
Homology Medicines plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- ARCH Venture Partners: Verified investor in Series C
- Temasek Holdings: Verified investor in Series C
- Fidelity: Verified investor in Series C
- Deerfield Management: Verified investor in Series C
Company Info
Investors (4)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free